Noxafil

posaconazole · POSACONAZOLE 18 mg/mL · Solution · Intravenous · Merck Sharp & Dohme LLC

NDC 00085-4331-01 · 1 VIAL, GLASS in 1 CARTON / 16.7 mL in 1 VIAL, GLASS · NDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. A Class II recall hit this product in the past year (Merck Sharp & Dohme LLC).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Part D plans paid (avg)$13.10per dosage unitgross, before rebates — matched by drug name · 2024
Federal ceiling (Big4)$304.49per unitMerck Sharp & Dohme LLC · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$530.45

Reported to Texas DSHS · 2026 annual filing · Merck Sharp & Dohme LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$208,306

28 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 3 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $1,171.66 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA205596
TE code: —
Approval date: Mar 13, 2014
Patents / exclusivity: 6 patents, 2 exclusivities

Type	Number / code	Expires
exclusivity	NPP	Jan 27, 2029
exclusivity	ODE-355	Jun 17, 2028
patent	9493582	Feb 27, 2033
patent	9023790	Jul 4, 2031
patent	9358297	Jun 24, 2031
patent	10117951	Mar 13, 2029
patent	8410077	Mar 13, 2029
patent	9750822	Mar 13, 2029

Shortage history

Planned discontinuation — Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)Dec 2, 2025

Recalls (this NDC)

Class II · OngoingDec 12, 2025
Merck Sharp & Dohme LLC — Presence of particulate matter: potential presence of metal particulates in the product.

Manufacturers of posaconazole (Solution)

Labeler	Strength	First seen	Last seen
Camber Pharmaceuticals, Inc.	POSACONAZOLE 18 mg/mL	Jul 15, 2026	Sep 2, 2026
FAREVA Mirabel	POSACONAZOLE 18 mg/mL	Jul 15, 2026	Sep 2, 2026
Merck Sharp & Dohme LLC	POSACONAZOLE 18 mg/mL	Jul 15, 2026	Sep 2, 2026
Mylan Institutional LLC	POSACONAZOLE 18 mg/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Noxafil — NDC 00085-4331-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00085433101.

Free to cite with attribution — see how the data is put together.